AERI - Aerie Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aerie Pharmaceuticals, Inc.

4301 Emperor Boulevard
Suite 400
Durham, NC 27703
United States
919-237-5300
http://www.aeriepharma.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees353

Key Executives

NameTitlePayExercisedYear Born
Dr. Vicente J. Anido Jr.CEO & Chairman1.16M11.84M1953
Mr. Thomas A. MitroPres & COO621k10.85M1958
Dr. Casey C. KopczynskiCo-Founder & Chief Scientific Officer578.03k169.56k1961
Mr. Richard James Rubino CPACFO, Sec. & Treasurer631.12kN/A1958
Mr. John W. LaRocca Esq.Gen. Counsel & Assistant Sec.521.07kN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Corporate Governance

Aerie Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.